中华临床医师杂志(电子版) 2017年2月,11卷3期

临床论著

急性进展性缺血性脑卒中血管内治疗的疗效分析

李娟 赵芳芳 宁方波 刘新红 张馨娜 梁迎春

271000 山东省泰安市中心医院神经内科
梁迎春,Email: qimaoer204@163.com

摘要:  目的 探讨急性进展性缺血性脑卒中血管内治疗的临床疗效。方法 选取脑卒中患者共44例,其中血管内治疗组21例,药物治疗组23例。记录两组入院时美国国立卫生研究院卒中量表(NIHSS)评分,病情进展后NIHSS评分,手术后或药物治疗后3 d NIHSS评分以及发病90 d NIHSS评分和改良Rankin量表(mRS)评分。采用t检验分析对比两组数据之间的差异。结果 血管内治疗组与药物治疗组相比较,入院时NIHSS评分分别为(3.8±2.1)分与(4.8±1.1)分,病情进展后分别为(19.8±4.1)分与(21.8±3.1)分,差异无统计学意义。手术后或药物治疗后3 d NIHSS评分分别为(9.8±3.1)分与(25.8±5.1)分,比较差异有统计学意义(P<0.01)。发病90 d NIHSS评分分别为(5.0±1.6)分与(14.8±3.7)分,比较差异有统计学意义(P<0.01);mRS评分分别为(2.0±0.5)分与(4.3±0.4)分,比较差异有统计学意义(P<0.05)。结论 血管内治疗是治疗急性进展性缺血性卒中的一种有效的方法,能够在一定程度上减轻患者肢体残疾水平和改善生活质量。

关键词: 进展性缺血性卒中; 血管内治疗; NIHSS评分; mRS评分

Efficacy analysis of endovascular treatment for acute progressive ischemic stroke

i Juan, Zhao Fangfang, Ning Fangbo, Liu Xinhong, Zhang Xinna, Liang Yingchun.

Department of Neurology, Tai'an City Central Hospital, Tai'an 271000, China
Liang Yingchun, Email: qimaoer204@163.com

Abstract:  Objective To explore efficacy analysis of endovascular treatment for acute progressive ischemic stroke. Methods The clinical data of 44 patients with acute progressive ischemic stroke treated in hospital were analyzed. Of them, 21 patients were in the endovascular treatment group and 23 patients were in the drug treatment group. The NIHSS scores and mRS scores of two groups of patients were recorded at different periods. Results NIHSS score was 3.8±2.1 and 4.8±1.1 on admission and 19.8±4.1 and 21.8±3.1 at the time of progression, respectively. There was no statistically significant difference between the endovascular treatment group and the drug treatment group. There was significant difference in the score of 9.8±3.1 and 25.8±5.1 at three days after operation or drug treatment (P<0.01). There was significant difference between NIHSS score of 5.0±1.6 and 14.8±3.7 for two groups at 90 days after onset (P<0.01). There was significant difference between 2.0±0.5 and 4.3±0.4 in mRS score (P<0.05). Conclusions Endovascular treatment for acute progressive ischemic stroke is feasible. To some extent, it can reduce disability of patients and improve the quality of life.

Keywords:Progressive ischemic stroke; Endovascular treatment; NIHSS scores; mRS scores

+ 字体 -

参考文献

  [1] 陈万青, 张思维, 邹小农, 等. 2004-2005年中国肺癌死亡情况分析[J]. 中华预防医学杂志, 2010, 44(5): 378-382.

  [2] 何安南. 支气管镜检查在早期肺癌中的诊断价值[J]. 实用老年医学, 2012, 26(1): 74.

  [3] 熊杰, 白生华, 徐万清, 等. 血清肿瘤标志物联合检测对肺癌的诊断价值[J]. 现代肿瘤医学, 2012, 20(3): 536.

  [4] 周超, 胡斌, 俞江月, 等. 血清肿瘤标志物检测在肺癌诊断及疗效评估中价值[J]. 中华实用诊断与治疗杂志, 2011, 6(3): 245-247.

  [5] 程黎明, 邓玲燕, 李辉军, 等. 血清肿瘤标志物检测在肺癌诊断与临床分期中的应用[J]. 华中科技大学学报(医学版), 2010, 39(3): 402-407.

  [6] Tas F, Bilgin E, Tastekin D, et al. Clinical significance of serum laminin levels in patients with lung cancer[J]. Biomed Rep, 2016, 4(4): 485-488.

  [7] 刘枋, 林志强, 陈慧菁, 等. 血清Cyfra21-1和SELDI技术联合检测肺鳞癌的临床意义[J]. 肿瘤防治研究, 2011, 38(5): 539-541, 561.

  [8] 黄宗华, 徐丹丹, 张飞艳, 等. 血清ProGRP和NSE对评价小细胞肺癌化疗疗效及其预后的价值[J]. 中华肿瘤防治杂志, 2015, 22(22): 1774-1778.

  [9] 陈阳阳, 张洁, 徐国宾. 晚期肺癌患者一线化疗后6种血清肿瘤标志物水平的变化及意义[J]. 临床检验杂志, 2015, 33(2): 124-129.

  [10] Terada KY, Ahn HJ, Kessel B. Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial[J]. J Gynecol Oncol, 2016, 27(3): e25.

  [11] Cheung M, Kadariya Y, Pei J, et al. An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation[J]. Cancer Genet, 2015, 208(10): 502-507.

  [12] Wang B, He YJ, Tian YX, et al. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21- 1 for diagnosis of lung cancer[J]. Asian Pac J Cancer Prev, 2014, 15(22): 9611-9614.

(编辑:戚红丹 收稿日期:2016-09-22)